title: Folate pathway polymorphisms predict deficits in attention and processing speed after childhood leukemia therapy.
abstract: BACKGROUND
  Neurocognitive impairment occurs in 20-40% of childhood acute lymphoblastic leukemia (ALL) survivors, possibly mediated by folate depletion and homocysteine elevation following methotrexate treatment. We evaluated the relationship between folate pathway polymorphisms and neurocognitive impairment after childhood ALL chemotherapy.
  
  
  METHODS
  Seventy-two childhood ALL survivors treated with chemotherapy alone underwent a neurocognitive battery consisting of: Trail Making Tests A (TMTA) and B (TMTB), Grooved Pegboard Test Dominant-Hand and Nondominant-Hand, Digit Span subtest, and Verbal Fluency Test. We performed genotyping for: 10-methylenetetrahydrofolate reductase (MTHFR 677C>T and MTHFR 1298A>C), serine hydroxymethyltransferase (SHMT 1420C>T), methionine synthase (MS 2756 A>G), methionine synthase reductase (MTRR 66A>G), and thymidylate synthase (TSER). Student's two sample t-test and analysis of covariance were used to compare test scores by genotype.
  
  
  RESULTS
  General impairment on the neurocognitive battery was related to MTHFR 1298A>C (P = 0.03) and MS 2756A>G (P = 0.05). Specifically, survivors with MTHFR 1298AC/CC genotypes scored, on average, 13 points lower on TMTB than those with MTHFR 1298AA genotype (P = 0.001). The MS 2756AA genotype was associated with a 12.2 point lower mean TMTA score, compared to MS 2756 AG/GG genotypes (P = 0.01). The TSER 2R/3R and 3R/3R genotypes were associated with an 11.4 point lower mean score on TMTB, compared to the TSER 2R/2R genotype (P = 0.03). Survivors with ≥6 folate pathway risk alleles demonstrated a 9.5 point lower mean TMTA score (P = 0.06) and 14.5 point lower TMTB score (P = 0.002) than survivors with <6 risk alleles.
  
  
  CONCLUSIONS
  Folate pathway polymorphisms are associated with deficits in attention and processing speed after childhood ALL therapy.
authors: Department of Pediatrics, Baylor College of Medicine, Texas Children's Cancer Center, Houston, TX, USA. kykamdar@txccc.org
authors: Kala Y
authors: KY
authors: Kamdar
authors: Kevin R
authors: KR
authors: Krull
authors: Randa A
authors: RA
authors: El-Zein
authors: Pim
authors: P
authors: Brouwers
authors: Brian S
authors: BS
authors: Potter
authors: Lynnette L
authors: LL
authors: Harris
authors: Suzanne
authors: S
authors: Holm
authors: Zoann
authors: Z
authors: Dreyer
authors: Fernando
authors: F
authors: Scaglia
authors: Carol J
authors: CJ
authors: Etzel
authors: Melissa
authors: M
authors: Bondy
authors: M Fatih
authors: MF
authors: Okcu
references: Leuk Lymphoma. 2006 Dec;47(12):2488-504
references: 17169794
references: J Pediatr Psychol. 2005 Jan-Feb;30(1):79-84
references: 15610987
references: J Pediatr. 2010 Jun;156(6):978-984.e1
references: 20223480
references: J Clin Oncol. 1998 Apr;16(4):1505-11
references: 9552059
references: Dev Med Child Neurol. 2004 Dec;46(12):843-51
references: 15581159
references: Neurology. 2003 Aug 26;61(4):506-15
references: 12939425
references: J Pediatr. 2008 Jan;152(1):101-5
references: 18154909
references: N Engl J Med. 2002 Feb 14;346(7):476-83
references: 11844848
references: J Clin Oncol. 1997 Aug;15(8):2800-6
references: 9256122
references: J Pediatr Psychol. 2001 Jan-Feb;26(1):1-9
references: 11145727
references: Ment Retard Dev Disabil Res Rev. 2006;12(3):174-83
references: 17061283
references: J Child Neurol. 1988 Jan;3(1):53-62
references: 3343495
references: J Child Neurol. 2005 Feb;20(2):129-33
references: 15794179
references: Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3059-64
references: 9501215
references: Haematologica. 2003 Feb;88(2):159-66
references: 12604405
references: Pediatr Blood Cancer. 2009 Jan;52(1):26-32
references: 19006245
references: J Pediatr Hematol Oncol. 2004 Jun;26(6):386-8
references: 15167354
references: Cancer. 2003 Feb 15;97(4):1115-26
references: 12569614
references: J Pediatr Psychol. 2007 Mar;32(2):189-93
references: 16675716
references: Chemotherapy. 2003 May;49(1-2):92-104
references: 12714818
references: Pediatr Blood Cancer. 2009 Apr;52(4):447-54
references: 19061221
references: Cell Struct Funct. 1995 Jun;20(3):191-7
references: 7586009
references: Cancer. 2000 Aug 15;89(4):925-31
references: 10951359
references: Arch Clin Neuropsychol. 2000 Oct;15(7):603-30
references: 14590198
references: J Autism Dev Disord. 2008 Jul;38(6):1170-7
references: 18027081
references: J Clin Oncol. 2006 Aug 20;24(24):3858-64
references: 16921038
references: J Rheumatol. 2008 Nov;35(11):2179-86
references: 18785313
references: Hum Genet. 2002 Sep;111(3):299-302
references: 12215845
references: Pharmacogenomics. 2005 Apr;6(3):293-302
references: 16013960
references: Pediatr Blood Cancer. 2005 Sep;45(3):281-90
references: 15806539
references: Nutr Rev. 2004 Jun;62(6 Pt 2):S3-12; discussion S13
references: 15298442
references: Schizophr Res. 2007 May;92(1-3):181-8
references: 17344026
references: J Clin Oncol. 2007 Nov 1;25(31):4914-21
references: 17971588
references: Am J Epidemiol. 2003 Apr 1;157(7):571-82
references: 12672676
references: Neurobiol Aging. 2006 Feb;27(2):334-43
references: 16399216
references: Am J Hum Genet. 2009 Sep;85(3):354-63
references: 19732866
references: Pediatr Blood Cancer. 2008 Jul;51(1):99-104
references: 18322925
references: J Clin Oncol. 2008 Sep 1;26(25):4138-43
references: 18757327
references: Am J Pharmacogenomics. 2001;1(3):189-201
references: 12083967